Alzamend Neuro (ALZN) Cash from Financing Activities (2020 - 2026)

Alzamend Neuro has disclosed Cash from Financing Activities across 6 years of filings, most recently posting $794844.0 for Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 46.63% year-over-year to $794844.0; the TTM figure through Apr 2026 stood at $4.8 million (down 53.74% YoY), while the FY2026 annual figure was $4.8 million, down 53.74% from the prior year.
• Cash from Financing Activities came in at $794844.0 for Q2 2026 at Alzamend Neuro, down from $4.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $6.3 million in Q4 2024 to a low of $400.0 in Q1 2022.
• Average Cash from Financing Activities over 4 years is $2.3 million, with a median of $1.7 million recorded in 2024.
• Year-over-year, Cash from Financing Activities slumped 99.95% in 2022 and surged 105.49% in 2025.
• Over 4 years, Cash from Financing Activities stood at $3.9 million in 2022, then soared by 59.78% to $6.3 million in 2024, then tumbled by 35.94% to $4.0 million in 2025, then plunged by 80.3% to $794844.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $794844.0 in Q2 2026, $4.0 million in Q3 2025, and $1.5 million in Q2 2025.